model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT00977431,NCT00977431,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform,Afatinib in Combination with Radiotherapy with or without Temozolomide in Newly Diagnosed Glioblastoma Multiforme,True,0.97,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,"Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM","A phase I, open-label, 3 + 3 dose-escalation trial to determine the maximum tolerated dose of afatinib in combination with radiotherapy, with or without temozolomide, in patients with newly-diagnosed glioblastoma multiforme",True,0.96,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with:

* radiotherapy alone (in patients with an unmethylated (functioning) MGMT gene regulator) or
* radiotherapy and Temozolomide (in patients with a methylated (silenced) O6-methylguanine-DNA methyltransferase gene (MGMT) to treat newly diagnosed patients with Grade IV Glioblastoma (primary brain cancer).","This phase I, open-label, dose-escalation clinical trial investigated the safety, tolerability, and maximum tolerated dose (MTD) of afatinib, an ErbB family blocker, when combined with radiotherapy (RT) with or without temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM). The study enrolled patients with histologically confirmed grade 4 malignant glioma and known O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation status. The trial included two treatment regimens: regimen M (afatinib + TMZ + RT) for patients with methylated MGMT promoters, and regimen U (afatinib + RT) for patients with unmethylated MGMT promoters. The primary endpoint was to determine the MTD of continuous daily afatinib in combination with RT, with or without concomitant TMZ treatment.",True,0.96,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,EV,EV,,"Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults and is associated with poor prognosis. Amplification or overexpression of the epidermal growth factor receptor (EGFR) gene occurs in approximately 40% and 60% of patients with GBM, respectively. Afatinib is an irreversible ErbB family blocker that targets EGFR (ErbB1), HER2 (ErbB2), and ErbB4, offering a broader inhibitory profile than first-generation EGFR tyrosine kinase inhibitors (TKIs) and demonstrating potential for central nervous system penetration.

This phase I trial employed a 3+3 dose-escalation design at five sites in the United Kingdom. Eligible patients were aged ≥18 and <70 years with newly diagnosed, histologically confirmed WHO grade 4 malignant glioma and known MGMT gene promoter methylation status. Patients received RT (2 Gy per fraction, 5 days per week for 6 weeks, total dose 60 Gy) in combination with afatinib at escalating doses (20, 30, or 40 mg/day) during the RT phase (days 1-42), followed by maintenance afatinib at 40 mg/day. In regimen M, patients also received TMZ 75 mg/m² daily during the RT phase, followed by up to six 28-day cycles of TMZ (150 mg/m² in cycle 1, 200 mg/m² in cycles 2-6, days 1-5 of each cycle).

The primary endpoint was MTD, defined as the highest afatinib dose at which no more than one of six patients experienced dose-limiting toxicity (DLT) during the RT phase. Secondary endpoints included safety (assessed via adverse events graded by CTCAE v3.0), objective tumor response rate (evaluated by investigator assessment using Macdonald criteria via gadolinium-enhanced MRI), and afatinib pharmacokinetics. Post hoc analysis examined time to disease progression.

Fifty-five patients were enrolled; 36 received at least one dose of trial medication (regimen M, n=20; regimen U, n=16). The MTD was determined as afatinib 30 mg/day in combination with daily TMZ and RT (regimen M), and afatinib 40 mg/day in combination with RT alone (regimen U). The most frequently reported adverse events were diarrhea, rash, and nausea/fatigue, consistent with the known safety profile of afatinib. Of evaluable patients, five (25%) receiving regimen M and one (6%) receiving regimen U achieved an objective response. Median time to disease progression was 434 days (95% CI 205-NA) for regimen M and 211 days (95% CI 101-NA) for regimen U. Pharmacokinetic profiles were consistent with previous afatinib monotherapy studies. The study concluded that afatinib in combination with RT, with or without TMZ, has a manageable safety profile in patients with newly diagnosed GBM, and future studies should incorporate biomarker-based patient preselection, particularly for EGFR aberrations.",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,['Glioblastoma'],"['Glioblastoma Multiforme', 'Malignant Glioma', 'Grade 4 Glioma', 'Brain Neoplasms', 'Central Nervous System Neoplasms']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Glioblastoma', 'GBM', 'Afatinib', 'ErbB inhibitor', 'EGFR', 'Epidermal Growth Factor Receptor', 'Radiotherapy', 'Temozolomide', 'MGMT methylation status', 'O6-methylguanine-DNA methyltransferase', 'Phase I trial', 'Dose-escalation study', 'Maximum tolerated dose', 'Newly diagnosed glioma', 'Biomarker-driven therapy', 'Tyrosine kinase inhibitor']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,TP,['PHASE1'],['PHASE1'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,NON_RANDOMIZED,NON_RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"This was a phase I, open-label, 3 + 3 dose-escalation trial in patients with newly-diagnosed malignant glioma. The study included two treatment regimens: regimen M (afatinib + TMZ in combination with RT) for patients with methylated MGMT status, and regimen U (afatinib in combination with RT without TMZ) for patients with unmethylated MGMT gene promoters. Following protocol amendment and determination of MTD in regimen U, all new patients were assigned to regimen M regardless of methylation status. Afatinib was administered in dose escalation cohorts of 20, 30, and 40 mg/day.",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,Open-label study with no masking,,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,FP,36,55,False,0.6,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].label,EV,EV,,Regimen M: Afatinib + TMZ + RT (Dose Escalation 40 mg),,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].label,EV,EV,,Regimen U: Afatinib + RT (Dose Escalation 20 mg),,,,ArmGroupLabel,protocolSection.armsInterventionsModule.armGroups.label,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].type,EV,EV,,EXPERIMENTAL,,,,ArmGroupType,protocolSection.armsInterventionsModule.armGroups.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].description,EV,EV,,"Patients with methylated MGMT promoter received afatinib 40 mg/day during both the RT phase (6 weeks, 60 Gy total dose) and maintenance, plus TMZ 75 mg/m² daily during RT, followed by TMZ maintenance cycles (150 mg/m² in cycle 1, 200 mg/m² in cycles 2–6, days 1–5 of each 28-day cycle for up to 6 cycles).",,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].description,EV,EV,,"Patients with unmethylated MGMT promoter received afatinib 20 mg/day during the RT phase (6 weeks, 60 Gy total dose) and 40 mg/day during maintenance, without concomitant TMZ.",,,,ArmGroupDescription,protocolSection.armsInterventionsModule.armGroups.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[2].interventionNames,EV,EV,,"['DRUG: Afatinib 40 mg/day (RT phase and maintenance)', 'DRUG: Temozolomide (TMZ)', 'RADIATION: Radiotherapy (RT)']",,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.armGroups[3].interventionNames,EV,EV,,"['DRUG: Afatinib 20 mg/day (RT phase)', 'DRUG: Afatinib 40 mg/day (maintenance)', 'RADIATION: Radiotherapy (RT)']",,,,ArmGroupInterventionName,protocolSection.armsInterventionsModule.armGroups.interventionNames,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Time to Disease Progression (TTP),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Calculated as the time between the first treatment date to the day following the first date with recorded progressive disease. Patients without progressive disease were censored at their most recent imaging date. Median and 95% confidence interval (CI) were calculated using Kaplan–Meier methodology.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,From the start of treatment until disease progression or most recent imaging date (up to approximately 24 months or more),,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion criteria:

1. Histologically-confirmed WHO Grade IV newly diagnosed malignant glioma.
2. Proven MGMT gene promoter methylation status
3. Available early postoperative Gd-enhanced MRI (within 72 hours after initial surgery). In case a patient did not perform a Gd-enhanced MRI within 72 hours post surgery, a Gd-MRI is to be performed prior to start of study treatment.
4. Age more or equal to 18 years and less than 70 years at entry
5. Karnofsky Performance Scale (KPS) more or equal to 70%
6. Patients receiving corticosteroids have to receive a stable or decreasing dose for at least 14 days before start of treatment.
7. Written informed consent that is consistent with local law and ICH- Good Clinical Practice (GCP) guidelines.

Exclusion criteria:

1. Less than two weeks from surgical resection or other major surgical procedure at start of treatment.
2. Planned surgery for other diseases
3. Placement of Gliadel® wafer at surgery.
4. Prior or planned radiotherapy of the cranium including brachytherapy and/or radiosurgery for GBM.
5. Treatment with other investigational drugs; participation in another clinical study including exposure to the investigational product within the past 4 weeks before start of therapy or concomitantly with this study.
6. Active infectious disease requiring intravenous therapy.
7. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
8. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea.
9. Patients with known pre-existing interstitial lung disease
10. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
11. Patient is less than 3 years free of another primary malignancy except: if the other primary malignancy is either not currently clinically significant or does not require active intervention (such as a basal cell skin cancer or a cervical carcinoma in situ). Existence of any other malignant disease is not allowed.
12. Cardiac left ventricular function with resting ejection fraction less than 50%.
13. Absolute neutrophil count (ANC) less than 1500/mm3.
14. Platelet count less than 100,000/mm3.
15. Bilirubin greater than 1.5 x upper limit of institutional norm.
16. Aspartate amino transferase (AST) greater than 3 x upper limit of institutional norm.
17. Serum creatinine greater than 1.5 x upper limit of institutional norm.
18. Patients who are sexually active and unwilling to use a medically acceptable method of contraception.
19. Pregnancy or breast-feeding.
20. Patients unable to comply with the protocol.
21. Known or suspected active drug or alcohol abuse.
22. Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.","**Inclusion Criteria:**
- Aged ≥18 and <70 years
- Newly-diagnosed, histologically-confirmed World Health Organization grade 4 malignant glioma
- Proven MGMT gene promoter methylation status (or tumor material available for testing)

**Exclusion Criteria:**
- Surgery within 2 weeks prior to the start of treatment or planned during the trial
- Placement of a Gliadel® wafer at surgery
- Prior radiotherapy of the cranium (including brachytherapy and/or radiosurgery for GBM)
- Treatment with other investigational drugs concomitantly with the study",True,0.9,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,TP,TP,69 Years,69 Years,True,1.0,exact,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
